Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.40 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.32 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6505668 | 0.77 | NPC1 (0.33) | — | |
| SCHEMBL29993075 | 0.73 | AHR (0.55) | EGLN2KMOFFAR1PTGS2PTGS1 | |
| SCHEMBL4496181 | 0.73 | ALOX5 (0.42) | — | |
| SCHEMBL5543084 | 0.72 | KMO (0.38) | EGLN2KMOPTGS2PTGS1ABL1 | |
| SCHEMBL6437984 | 0.70 | CYP1A2 (0.39) | — | |
| SCHEMBL30116872 | 0.69 | TAAR1 (0.53) | EGLN2AHR | |
| SCHEMBL31067161 | 0.69 | TAAR1 (0.53) | EGLN2AHR | |
| SCHEMBL20898196 | 0.69 | TAAR1 (0.53) | EGLN2AHR | |
| SCHEMBL30936103 | 0.69 | ESR2 (0.52) | EGLN2KMOFFAR1ERCC5FEN1 | |
| SCHEMBL1042848 | 0.69 | ESR2 (0.52) | EGLN2KMOFFAR1ERCC5FEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112933236-A | Combination therapy comprising an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer | 美国安进公司 | 2021-06-11 | — | — | CN | disclosed |